Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluering af et kunstig intelligens-baseret diagnostisk supportværktøj til ældre voksne i primærsektoren (INTERLACE)

21. september 2026 opdateret af: Gary Weissman, University of Pennsylvania

Fremme af diagnostisk ekspertise for ældre voksne gennem kollektiv intelligens og imitationslæring

Older adults commonly experience diagnostic errors that may lead to direct harms and increased healthcare costs. Older adults are especially at risk because of higher rates of comorbidity burden, medical complexity, frailty, and cognitive impairment. An artificial intelligence (AI) clinical decision support system (CDSS) offer a promising approach to promote diagnostic excellence for older adults.

The purpose of this study is to assess the acceptability and feasibility of a new AI CDSS for older adults in primary care. The goal of this AI CDSS is to provide diagnostic support during primary care visits (i.e., help make timely and accurate diagnoses) and support communication amongst patients, doctors, and caregivers about the patient's health.

In this study, participants will use the AI CDSS in a primary care visit and review its suggestions for diagnoses and tests. Afterwards, they will complete a feedback survey and interview where they share their thoughts about and experience using the AI CDSS.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

40

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

65 år og ældre (Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Clinicians

  1. Work in the University of Pennsylvania Health System
  2. Work in a primary care setting (i.e., Internal Medicine, Geriatric Medicine, Family Medicine, and Penn Primary Care)
  3. Actively treat adult patients who are 65 years old or older

Patients

  1. 65 years of age or older
  2. Have an upcoming encounter with a participating primary care clinician
  3. Indicate a new or worsening health concern that they wish to discuss at the upcoming encounter

Caregivers

  1. 18 years old or older
  2. Accompanying the participating patient during the encounter with the AI CDSS
  3. Identified by the patient as a caregiver

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Under the age of 18 years old
  2. Unable to provide informed consent in the opinion of the investigator
  3. Has a "Research Do Not Contact" status in the electronic health record

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Diagnostisk
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Use of INTERLACE tool in primary care visit

All participants will be asked to use INTERLACE in their primary care visit. The tool will be presented on an handheld electronic device and may be used by patients, caregivers, and primary clinicians at each visit. First, the patient will input their current symptoms into INTERLACE. Then, using these symptoms, latest vital signs, and the patient's medical history, INTERLACE will make suggestions for diagnoses and tests. Patients, caregivers, and clinicians can view and discuss these suggestions together to arrive at a potential diagnosis.

INTERLACE is an artificial intelligence-based clinical decision support tool. It uses a patient's medical history, vital signs, and current symptoms to make suggestions for diagnoses and tests. These suggestions can be considered and discussed amongst patients, caregivers, and clinicians during primary care visits to help find a good diagnosis for the patient's symptoms.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Feasibility of embedding the AI CDSS into a primary care visit
Tidsramme: From enrollment to the end of the study interview, up to two weeks

Participants will complete a Feasibility of Intervention Measure (FIM) via feedback survey following the primary care visit. Responses are measured on a 5-point Likert scale.

From enrollment to the end of the study interview, up to two weeks
Feasibility of embedding the AI CDSS into a primary care visit
Tidsramme: From enrollment until the end of the study interview, up to two weeks

Feasibility will also be assessed through brief survey questions asking whether participants experienced any barriers to using INTERLACE, whether it was useful during the visit, and how long it was used (all measured on a 7-point Likert scale), as well as open-ended questions in a semi-structured interview.

From enrollment until the end of the study interview, up to two weeks
Acceptability of embedding the AI CDSS into a primary care visit
Tidsramme: From enrollment until the end of the study interview, up to two weeks

Participants will complete the Acceptability of Intervention Measure (AIM) via feedback survey after the primary care visit. Responses to the AIM are measured on a 5-point Likert scale.

From enrollment until the end of the study interview, up to two weeks
Acceptability of embedding the AI CDSS into a primary care visit
Tidsramme: From enrollment until the end of the study interview, up to two weeks

Participants will also complete a modified version of the Technology Acceptance model (TAM). Responses to the TAM are measured on a 7-point Likert scale.

From enrollment until the end of the study interview, up to two weeks
Acceptability of embedding the AI CDSS into a primary care visit
Tidsramme: From enrollment until the end of the study interview, up to two weeks

Participants will complete a Net Promoter Score assessing the likelihood that they would recommend the AI CDSS to others at the end of the survey. This will be measured on a 10-point scale.

From enrollment until the end of the study interview, up to two weeks
Acceptability of embedding the AI CDSS into a primary care visit
Tidsramme: From enrollment until the end of the study interview, up to two weeks

Acceptability will also be assessed through brief survey questions assessing whether INTERLACE caused distress (measured on a 7 point Likert scale), as well as open-ended questions in a semi-structured interview.

From enrollment until the end of the study interview, up to two weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Gary E Weissman, MD, MSPH, University of Pennsylvania

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. oktober 2026

Primær færdiggørelse (Anslået)

1. januar 2027

Studieafslutning (Anslået)

1. januar 2027

Datoer for studieregistrering

Først indsendt

9. april 2026

Først indsendt, der opfyldte QC-kriterier

20. april 2026

Først opslået (Faktiske)

28. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

21. september 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 852952

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner